Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2026-04-21 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于营业收入扣除事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查意见" (Special Audit Opinion) regarding the deduction of operating income for the fiscal year 2025. It is issued by a certified public accounting firm and references an audit report number. The content includes a detailed breakdown of operating income deductions and an auditor's opinion on the compliance of this financial information with regulatory requirements from the Shanghai Stock Exchange. The document length is 2584 characters, which is relatively short but contains substantive audit findings and financial details specific to a particular fiscal year. This is not a full annual report but a standalone audit-related report focusing on a specific financial aspect (operating income deductions). It is not a mere announcement or certification but a detailed audit opinion document. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2025
2026-04-21 Chinese
长春百克生物科技股份公司关于独立董事2025年度独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report on the independence self-assessment of independent directors for the year 2025 by the board of Changchun Baike Biotechnology Co., Ltd. It references regulatory rules about independent directors and confirms their independence status. The document is short (438 characters) and focuses on governance and board-related information rather than financial data or meeting materials. It is not an announcement of voting results, nor a full annual or interim report. The content fits best under Board/Management Information (MANG) as it relates to board member status and governance compliance.
2026-04-21 Chinese
国泰海通证券股份有限公司关于百克生物2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期归属条件未成就并作废部分已授予但尚未归属的限制性股票的公告之独立财务顾问意见
Board/Management Information Classification · 95% confidence The document is an independent financial advisor opinion report regarding the cancellation of certain unvested restricted stocks under a 2022 restricted stock incentive plan for Changchun Baike Biotechnology Co., Ltd. It includes detailed descriptions of board and supervisory meetings, approvals, and compliance with relevant laws and regulations. The content focuses on the stock incentive plan, its approval process, and the impact of canceling unvested shares. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The document is a detailed advisory opinion related to management and board decisions on stock incentives, which aligns with Board/Management Information filings. Therefore, the appropriate classification is MANG (Board/Management Information). The document length (4862 characters) and detailed content support this classification with high confidence.
2026-04-21 Chinese
长春百克生物科技股份公司2025年度环境、社会和公司治理报告
Environmental & Social Information Classification · 100% confidence The document is titled "环境、社会和公司治理报告" which translates to "Environmental, Social and Governance Report" for the year 2025. It is issued by 长春百克生物科技股份公司, a company listed on the Shanghai Stock Exchange Sci-Tech Innovation Board. The content extensively covers ESG topics such as environmental compliance, energy management, water resource management, governance structure related to ESG, social responsibility, and sustainability initiatives. The document references ESG standards, regulatory guidelines, and includes detailed disclosures on environmental and social performance. There is no indication that this is an annual financial report, earnings release, or any other financial filing. The document is a comprehensive ESG report, matching the description of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or summary.
2026-04-21 Chinese
长春百克生物科技股份公司关于2025年度拟不进行利润分配的公告
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement from Changchun Baike Biotechnology Co., Ltd. regarding the company's profit distribution plan for the fiscal year 2025. It states that the company proposes not to distribute cash dividends, not to convert capital reserves into shares, and not to issue bonus shares. The announcement includes detailed explanations about the company's financial performance, negative net profit, cash flow, and future plans, but it is primarily focused on the profit distribution proposal and its rationale. The document is relatively short (3212 characters) and structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it fits the profile of a Notice of Dividend Amount or Dividend Distribution Announcement, as it specifically addresses the dividend decision and related shareholder information. Therefore, the most appropriate classification is Notice of Dividend Amount (DIV).
2026-04-21 Chinese
长春百克生物科技股份公司审计报告
Regulatory Filings
2026-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.